<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefadroxil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefadroxil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefadroxil: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11822" href="/d/html/11822.html" rel="external">see "Cefadroxil: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13123" href="/d/html/13123.html" rel="external">see "Cefadroxil: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866222"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Cefadroxil;</li>
<li>PRO-Cefadroxil-500 [DSC];</li>
<li>TEVA-Cefadroxil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F147039"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (First Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F146999"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a3752da-fee2-4fe5-a538-d40b09875e03">Prosthetic joint infection, staphylococci, chronic oral antimicrobial suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection, staphylococci (oxacillin-susceptible), chronic oral antimicrobial suppression (off-label use):</b>
<b>Oral: </b>500 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not an appropriate agent if methicillin-resistant <i>Staphylococcus aureus</i> is suspected or confirmed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis (nonpurulent)/erysipelas, mild, treatment (alternative agent):</i>
<b>Oral:</b> 1 g once daily or 500 mg twice daily for 5 days; duration may be extended up to 14 days if not resolved/slow response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4016827','lexi-content-ref-12182257','lexi-content-ref-24973422','lexi-content-ref-Spelman.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4016827','lexi-content-ref-12182257','lexi-content-ref-24973422','lexi-content-ref-Spelman.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cellulitis, long-term suppression of recurrent infection:</i>
<b>Note:</b> For patients with recurrent presumptive staphylococcal cellulitis at the same anatomical site despite addressing predisposing factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>500 mg twice daily after completion of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent</b>
<b> for mild, nonanaphylactic penicillin allergy<b>):</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pichichero.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pichichero.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 g once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Pichichero.2018','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Pichichero.2018','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use only when preferred agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3484773','lexi-content-ref-21292654','lexi-content-ref-2197091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3484773','lexi-content-ref-21292654','lexi-content-ref-2197091'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection):</i>
<b>Oral: </b>500 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3484773','lexi-content-ref-Hooton.2018a','lexi-content-ref-Gupta.1','lexi-content-ref-7654268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3484773','lexi-content-ref-Hooton.2018a','lexi-content-ref-Gupta.1','lexi-content-ref-7654268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis):</i>
<b>Oral:</b> 1 g twice daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-2197091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-2197091'])">Ref</a></span>); for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2018a','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2018a','lexi-content-ref-30535100'])">Ref</a></span>). <b>Note:</b> Oral beta-lactam therapy should generally follow appropriate parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2018b','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2018b','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991210"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Cefadroxil Maintenance Doses for Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is 1 g every 24 hours or 500 mg every 12 hours<sup>b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual dose is 1 g twice daily<sup>b,c</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Administer an initial dose of 1 g in all patients, then begin the recommended maintenance dose.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Expert opinion.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Leroy 1982.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">≥40 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;20 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (63% removal following a 6- to 8-hour hemodialysis session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7142092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7142092'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 1 g every 24 hours or 500 mg every 12 hours: Administer 1 g once initially, followed by 500 mg 3 times weekly after hemodialysis sessions on hemodialysis days only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 1 g every 12 hours: Administer 1 g once initially, followed by 1 g 3 times weekly after hemodialysis sessions on hemodialysis days only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-456077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-456077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 1 g every 24 hours or 500 mg every 12 hours: 1 g once initially, followed by 500 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If the usual recommended dose is 1 g every 12 hours: 1 g once initially followed by 500 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988415"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doe drugH1Div" id="F147000"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F147018"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13123" href="/d/html/13123.html" rel="external">see "Cefadroxil: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Oral: 30 mg/kg/day divided every 12 hours; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c00357b8-de45-4183-8d7b-6cc88f991ddf">Impetigo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Impetigo:</b> Children and Adolescents: Oral: 30 mg/kg/day once daily or in divided doses every 12 hours; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Recommended duration is 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-32550690']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-32550690'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5285a396-852e-4b3d-b4b0-d754f216f7be">Osteoarticular infection, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection, acute (eg, septic [bacterial] arthritis, osteomyelitis): </b>
<i>Step down therapy following parenteral treatment: </i>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 75 to 150 mg/kg/day in divided doses every 6 to 8 hours; maximum dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29920709','lexi-content-ref-32123023','lexi-content-ref-28708801','lexi-content-ref-29290233','lexi-content-ref-20842069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29920709','lexi-content-ref-32123023','lexi-content-ref-28708801','lexi-content-ref-29290233','lexi-content-ref-20842069'])">Ref</a></span>). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration should be individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-34350458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-34350458'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b> Children and Adolescents: Oral: 30 mg/kg/day in divided doses every 12 hours; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12690270','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12690270','lexi-content-ref-Manu.1'])">Ref</a></span>). Typical duration for uncomplicated infection is 5 days, but may be extended if clinical response is inadequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 30 mg/kg/day once daily or in divided doses every 12 hours for 10 days; maximum daily dose: 1,000 mg/<b>day </b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Children and Adolescents: Oral: 30 mg/kg/day divided every 12 hours; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; typical duration is 7 to 14 days, though it may be as short as 3 to 5 days (eg, for uncomplicated cystitis in patients ≥2 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-32364593','lexi-content-ref-34860955','lexi-content-ref-25477258'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083950"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing based on a usual dose of 30 mg/kg/day in divided doses every 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: Oral: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Oral: 15 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Oral: 15 mg/kg/dose every 36 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Dialyzable (63% removal following a 6- to 8-hour hemodialysis session) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7142092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7142092'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). Based on adult pharmacokinetic studies, three-times-weekly dosing after dialysis has also been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7142092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7142092'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 mg/kg/dose every 36 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51083951"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F146964"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: postmarketing, and/or case reports: Abdominal pain, agranulocytosis, anaphylaxis, angioedema, arthralgia, cholestasis, <i>Clostridioides difficile</i>-associated diarrhea, dyspepsia, erythema multiforme, erythematous rash, fever, genital candidiasis, hepatic failure, increased serum transaminases, maculopapular rash, nausea, neutropenia, pruritus, pseudomembranous colitis, serum sickness, Stevens-Johnson syndrome, thrombocytopenia, urticaria, vaginitis, vomiting</p></div>
<div class="block coi drugH1Div" id="F146980"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefadroxil, any component of the formulation, or other cephalosporins</p></div>
<div class="block war drugH1Div" id="F146961"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colitis: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute/1.73 m<sup>2</sup>); dosage adjustment may be needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suspension: May contain sulfur dioxide (sulfite); hypersensitivity reactions, including anaphylaxis and/or asthmatic exacerbations, may occur (may be life threatening).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878370"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F146973"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (100 mL); 500 mg/5 mL (75 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g</p></div>
<div class="block geq drugH1Div" id="F146957"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F146982"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cefadroxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cefadroxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $0.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cefadroxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $7.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866223"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block adm drugH1Div" id="F146977"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Administer without regards to meals; administration with food may diminish GI complaints.</p></div>
<div class="block admp drugH1Div" id="F52612375"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food; administration with food may decrease GI complaints; shake suspension well before use.</p></div>
<div class="block use drugH1Div" id="F146976"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infections:</b> Treatment of skin and soft tissue infections caused by staphylococci and/or streptococci.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A:</b> Treatment of pharyngitis and/or tonsillitis caused by <i>Streptococcus pyogenes</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Treatment of urinary tract infections caused by <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, and <i>Klebsiella</i> species.</p></div>
<div class="block off-label drugH1Div" id="F25475323"><span class="drugH1">Use: Off-Label: Adult</span><p>Prosthetic joint infection with Staphylococci (oxacillin-susceptible)</p></div>
<div class="block mst drugH1Div" id="F27978617"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Duricef may be confused with Ultracet </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298984"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F146966"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5944424"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefadroxil crosses the placenta (Takase 1980).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, cephalosporin antibiotics are generally considered compatible for use during pregnancy; however, outcome information specific to maternal use of cefadroxil during pregnancy is limited compared to other cephalosporins (Ailes 2016; Bookstaver 2015; Crider 2009; Czeizel 2001; Lamont 2014; Muanda 2017a; Muanda 2017b; Nathorst-Böös 1995; Schedvins 1986).</p></div>
<div class="block brc drugH1Div" id="F146983"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cefadroxil is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The relative infant dose (RID) of cefadroxil is 2.6% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 1 g/day.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of cefadroxil was calculated using a milk concentration of 2.4 mcg/mL, providing an estimated daily infant dose via breast milk of 360 mcg/kg/day. This milk concentration was obtained following maternal administration of cefadroxil 1 g to 6 mothers on the third postpartum day. The mean peak milk concentration was 1.83 mcg/mL (range: 1.2 to 2.4 mcg/mL) at 6 to 7 hours after the dose (Kafetzis 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002). The manufacturer recommends that caution be exercised when administering cefadroxil to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F146971"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F146960"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F146979"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and well absorbed from GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.31 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 2.3 ± 0.5 hours (Windorfer 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Mean range: ~1.3 to 1.8 hours (Ginsburg 1978; Windorfer 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1 to 2 hours; 20 to 24 hours in renal failure.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak serum concentration: Within 70 to 90 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;90% as unchanged drug within 24 hours).</p></div>
<div class="block phksp drugH1Div" id="F58639412"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC). Goal: ≥40% to 50% (fT) &gt; MIC (bacteriostatic), ≥60% to 70% (bactericidal) (Craig 1996; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug concentration in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients, C<sub>max</sub> (peak), single dose, oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≤10 months of age: 25 mg/kg: 24.8 ± 5.3 mg/L (Windorfer 1982).</p>
<p style="text-indent:-2em;margin-left:10em;">Children:</p>
<p style="text-indent:-2em;margin-left:12em;">15 mg/kg: ≤11 years of age: 11 to 13.7 mg/L (Ginsburg 1982).</p>
<p style="text-indent:-2em;margin-left:12em;">25 mg/kg: ≤5 years of age: 21.2 ± 5 mg/L (Windorfer 1982).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, C<sub>max</sub> (peak), oral:</p>
<p style="text-indent:-2em;margin-left:10em;">Single dose:</p>
<p style="text-indent:-2em;margin-left:12em;">500 mg: 17.9 ± 1 mg/L (La Rosa 1982).</p>
<p style="text-indent:-2em;margin-left:12em;">1 g: 35.2 ± 0.6 mg/L (La Rosa 1982).</p>
<p style="text-indent:-2em;margin-left:10em;">Steady state: 1 g every 8 hours: 35.5 ± 5.9 mg/L (Hampel 1982).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect</i>
<i>: </i>Generally &lt;1 hour; varies by organism (Craig 1991; Craig 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146984"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cefadrox | Droxil | Duricef | Kefloxin | Roxil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefacar | Cefacilina | Cefadrox | Cefadroxilo Fabra | Cefamar | Cefasin | Cefatenk | Droxil | Kandicin | Klondroxil | Versatic</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Duracef</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adocef | Adocil | Adora | Arocef | Cedril | Cefador | Cefcare | Droxil | Ficef | Fodexil | Licef | Sefadol | Sefanid | Twicef</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil merck-generics | Cefadroxil sandoz | Duracef | Moxacef</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Asmodrox | Biodroxyl | Oracefal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Droxcef | Duracef | Valdocef</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cedroxil | Cefadroxila | Cefadroxon | Cefamox | Cefanaxil | Celocortin | Celoxin | Drocef | Drofaxil | Neo cefadril</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Asmodrox | Bicef | Biodroxil | Kefdil | Oracefal | Oradroxyl | Saiforal | Sandrox | Sandrox ds | Serdroxil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adroxef | Biodroxil | Biogran | Cefadroxilo | Cefamox | Rafemox | Tridocylon</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bai meng | Ding ke | Heng lin | Ji da wei de | Ji sai ou | Jin duo xin | Kang ke | Ke li xin | Li xin qi | Lv xin | Ou yi | Sai fu xi | Sai qiao xi | Sheng ou | Shu yi | Xi feng ling | Xian an | Xian feng jiu | Yuan xing mie di</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aurodrox | Biodroxil | Cefadroxilo | Duracef | Fadrox | Fazotec | Nafamed | Novadrox | Udrocef | Zolpra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cedrox | Duracef | Valdocef</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil beta | Cefadroxil sandoz | Gruencef</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bacteram | Biodroxil | Cedroxin | Cefa | Cefadrox | Cefadroxilo | Cefadroxilo Alfa | Cepha | Drocicef | Duracef | Garaxil | Lapricef | Lufradoxilo | Ossimixina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cefadroxilo | Ceforal | Cetralon | Droxilon | Duracef</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Duracef | Vedrox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cefaxoral | Cefex | Curisafe | Duricef | Ibidroxil | Ibidroxyl | Longicef</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxilo | Duracef</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil generic | Cefadroxil Generics | Cefadroxil sandoz | Duracef</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil Biogaran | Cefadroxil g gam | Cefadroxil gnr | Cefadroxil ivax | Cefadroxil merck | Cefadroxil Ratiopharm | Cefadroxil teva | Oracefal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cefalom | Cyclomycine k | Kleotrat | Moxacef</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amben | Biodroxil | Droxion | Duracef | Duraxil | Qualidrox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alxil | Ancefa | Bidicef | Biodroxil | Cefadroxil Soho | Cefat | Cefco | Dexacef | Dexadrox | Doxef | Droxal | Droxefa | Duricef | Ethicef | Grafacef | Kenfaxil | Lactacef | Lapicef | Librocef | Longcef | Lostacef | Opicef | Osadrox | Pyricef | Q cef | Qidrox | Renasistin | Sedrofen | Staforin | Tisacef | Valos | Vocefa | Widrox | Yaricef</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ultracef</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Duracef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acudrox | Adrocef | Anodox | Apdil | Aroxil | Bicef | Bid | Bidel | Bludrox | Bonaxyl | Cdr | Cedro | Cedrox | Cedroxil | Cedroxin | Cefabid | Cefad | Cefadrol | Cefadrox | Cefadur | Cefastar | Cefcare | Cefdronat | Cefind | Ceflad | Cefodril | Cefom | Ceforange | Cefoxid | Cefoxil | Cefril | Cefriz | Ceftic | Cefty | Cefzen | Cepdox | Cephbid | Cetron | Cexil | Codroxil | Cosdrox | Credroxil | Dax | Decacadroxil | Delcef | Doxycard | Droxibid | Droxibid p | Droxicef | Droxilite | Droxycad | Droxyceph | Droxyl | Duracef | Duroxyl | Eliminate | Endroxyl | Eudrox | Fedexil | Gigacef | Infadrox | Keecef | Kefdil | Kefexyl | Kefloxin | Kefzen | Kidrox | Lactocef | Lydroxil | Megadrox | Modcef | Neodrox | Nephelex | Ococef | Odoxil | Pd roxil | Pendrox | Puredrox | Qceph | Ridrox | Safedrox | Seadrox | Sunidrox | Swiceff | Vepan | Vindrox | Vistadrox | Waladrox | Zadro | Zedoxil | Zendrox | Zendroxyl | Zoxil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cefadril | Cephos | Droxicef | Oradroxil</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cedrox | Cefadril | Cephos | Droxicef | Droxil | Duricef | Midroxil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cefadron | Dolucefan | Sedral banyu | Sedral torii | Sumacef bristol myers | Sumacef mochida | Sumacerud | Sumacerud choseido</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Actidrox | Bidcef | Biodroxil | C drox | Cedril | Cefamed | Cefvac | Cexil | Curisafe | Dawadroxyl | Drox | Duraxyl | Flamicef | Ibidroxil | Mydrox | Odoxil | Vedrox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aju cefadroxil | Anfadrox | Aprogen cefadroxil | Bidcef | Camex | Cefacel | Cefacell | Cefacil | Cefadil | Cefadro | Cefadrone | Cefadroxil yungjin | Cefaric | Cefaroxil | Cefodril | Cefoxil | Cefraxil | Cefroxil | Cellartcelaxin | Daewoong cefaroxil | Deroxil | Drocef | Drofa | Duricef | Evacef | Genuone cefadroxil | Glo cefadroxil | Hafroxil | Hanacef | Hanall cefadroxil | Hawon cefadroxil | Hwail cefadroxil | Il yang cefadroxil | Konicef | Kukje cefadroxil | Kwangdong cefadroxil | Medicefa | Neupad | Newgenpharm cefadroxil | Promerin | Safaraxil | Schnell cefadroxil | Unidroxil | Uricef | Urocef | Withucef</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Droxil | Duricef</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cedroxyl | Cefadril | Curisafe | Duricef | Midroxil | Roxil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Duracef</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil sandoz | Duracef | Moxacef</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Ceforal | Duracef</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Oracefal | Rodal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxilo | Cefamox | Cepotec | Duracef | Kefloxin | Teroxina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Androxyl | Anprodroxil | Cefradox | Droxyceph | Duricef | Kefloxin | Longcef | Sofidrox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Longcef</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Adroxef | Biodroxil | Cafazit | Cedronar | Cefadroxilo | Cefotrix | Cefrabiotic | Droxilar | Duracef | Kefdyl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cefadrox | Drolex | Droxil | Drozid | Lexipad | Wincocef</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A rox | Actacef | Acucef | Adrox | Ag-Drox | Aksocil | Aroxil | Astoxil | Baxef | Bd Rox | Bio oxil | Biodroxil | Bydoxil | C-doxil | Camex | Cedrox | Cedrox BD | Cefabact | Cefaroxin | Cefaxil | Cefroxil | Cepha | Ceroxil | Davox | Derfado | Drofin | Dromax | Droxim | Duraxic | Duricef | Efroxil | Envera | Evacef | Fedxil | Gefdrox | Grafadrox | Helicef | Hidrox | Indopol | Inforil | Jaycil | Joncef | Kanadrox | Kendrox | Lefdo | Maxdor | Maysa | Mecef | Neucef | Ofis | Oradrox | Oroxizaf | Osef | Oxibac | Ozix | Pedrox | Roxikef | Safdroxil | Say drox | Sephidrox | Sepnadox | Sidrox | Sionex | Sn rox | Sofilex | Solodrox | Sundox | Syroxil | Wedrox | Widrox | Xilporin | Z-drox | Zeboxil | Zylodrox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Duracef | Tadroxil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Duricef</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Biofaxil | Cefacile | Ceforal | Cefra-om</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxilo 1 g cefen guayaki | Cefadroxilo dutriec | Cefrazol | Justum | Novosporal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cefadril | Curisafe | Droxil | Longicef | Midroxil | Roxil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil terapia | Ceforan | Cexyl | Duracef</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Duracef</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo cefadroxil | Biodroxil | Cefadril | Cefadrox | Droxil | Midroxil | Ultracef</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxil merck nm | Cefadroxil mylan | Cefadroxil sandoz | Cefamox</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Androxyl | Biodroxil | Dexacef | Duricef | Sofidrox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Omnidrox | Valdiocef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cedrox | Duracef</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cefadril | Duricef</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cedrox | Oracefal | Oraxil | Saiforal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cefradur | Duricef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cefaxil | Cendmycin | Cephadroxil | Cephos | Dolucefan | Duracef | Ibidroxyl | Infaxil | Likodin | Lonfadroxil | Sedral | Ucefa | Wincef</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Biodroxil | Cedrox | Cefadrox | Cefangin | Duracef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Drox</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cefadroxilo | Cefamox | Curisafe</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aurodrox | Bidroxyl | Cedroxim | Cefadril | Cefadroxilo | Cefaval | Cefonax | Drocef | Droxifan | Grunicef | Kefloxin | Sanodril | Unidroxy</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Droxistad | Fabadroxil | Fimadro | Hataroxil dht | Opedroxil | Pyfadrox</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cefadrox | Cipadur | Dacef | Duracef</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cedril | Cexil | Odoxil | Zoxil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs. Combating antibiotic resistance [published correction appears in: <i>J Am Dent Assoc</i>. 2004;135(6):727.]. <i>J Am Dent Assoc</i>. 2004;135(4):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4016827">
<a name="4016827"></a>Ballantyne FN. Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections. <i>Clin Ther</i>. 1985;7(4):487-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/4016827/pubmed" id="4016827" target="_blank">4016827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12182257">
<a name="12182257"></a>Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. <i>Clin Ther</i>. 2002;24(7):1134-1147. doi:10.1016/s0149-2918(02)80024-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/12182257/pubmed" id="12182257" target="_blank">12182257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Cefadroxil capsules [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Cefadroxil capsules [prescribing information]. North Wales, PA: Teva Pharmaceuticals; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Cefadroxil capsules [product monograph]. Toronto, Ontario, Canada: Apotex Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Cefadroxil suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ranbaxy.1">
<a name="Ranbaxy.1"></a>Cefadroxil suspension [prescribing information]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Cefadroxil tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Cefadroxil tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis.</i> 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>CMNEEJ. </i>1991;13(16)121-128.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.<i> Pediatr Infect Dis J.</i> 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8588136">
<a name="8588136"></a>Cronberg S, Banke S, Bruno AM, et al. Ampicillin plus mecillinam vs. cefotaxime/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis. <i>Scand J Infect Dis</i>. 1995;27(5):463-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/8588136/pubmed" id="8588136" target="_blank">8588136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-436355">
<a name="436355"></a>Cutler RE, Blair AD, Kelly MR. Cefadroxil kinetics in patients with renal insufficiency. <i>Clin Pharmacol Ther</i>. 1979;25(5, pt 1):514-521.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/436355/pubmed" id="436355" target="_blank">436355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11349204">
<a name="11349204"></a>Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study. <i>Am J Obstet Gynecol</i>. 2001;184(6):1289-1296. doi:10.1067/mob.2001.113905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/11349204/pubmed" id="11349204" target="_blank">11349204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29920709">
<a name="29920709"></a>DeRonde KJ, Girotto JE, Nicolau DP. Management of pediatric acute hematogenous osteomyelitis, part I: antimicrobial stewardship approach and review of therapies for methicillin-susceptible <i>Staphylococcus aureus</i>, <i>Streptococcus pyogenes</i>, and <i>Kingella kingae</i>. <i>Pharmacotherapy</i>. 2018;38(9):947-966. doi:10.1002/phar.2160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/29920709/pubmed" id="29920709" target="_blank">29920709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32123023">
<a name="32123023"></a>Donaldson N, Sanders J, Child J, Parker S. Acute hematogenous bacterial osteoarticular infections in children. <i>Pediatr Rev</i>. 2020;41(3):120-136. doi:10.1542/pir.2018-0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/32123023/pubmed" id="32123023" target="_blank">32123023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR, Mandell GL. Drug therapy. Beta-lactam antibiotics (2). <i>N Engl J Med</i>. 1988;318(8):490-500. doi: 10.1056/NEJM198802253180806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277053">
<a name="3277053"></a>Donowitz GR, Mandell GL. Beta-Lactam antibiotics (1). <i>N Engl J Med</i>. 1988;318(7):419-426. doi: 10.1056/NEJM198802183180706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/3277053/pubmed" id="3277053" target="_blank">3277053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364593">
<a name="32364593"></a>Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. <i>JAMA Netw Open</i>. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/32364593/pubmed" id="32364593" target="_blank">32364593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7142090">
<a name="7142090"></a>Ginsburg CM. Comparative pharmacokinetics of cefadroxil, cefaclor, cephalexin and cephradine in infants and children. <i>J Antimicrob Chemother.</i> 1982;10(suppl B):27-31. doi:10.1093/jac/10.suppl_b.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7142090/pubmed" id="7142090" target="_blank">7142090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-666305">
<a name="666305"></a>Ginsburg CM, McCracken GH Jr, Clahsen JC, Thomas ML. Clinical pharmacology of cefadroxil in infants and children. <i>Antimicrob Agents Chemother</i>. 1978;13(5):845-848. doi:10.1128/AAC.13.5.845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/666305/pubmed" id="666305" target="_blank">666305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3484773">
<a name="3484773"></a>Greenberg RN, Reilly PM, Luppen KL, Weinandt WJ, Ellington LL, Bollinger MR. Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women. <i>J Infect Dis.</i> 1986;153(2):277-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/3484773/pubmed" id="3484773" target="_blank">3484773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2018b">
<a name="Hooton.2018b"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2018a">
<a name="Hooton.2018a"></a>Gupta K. Acute uncomplicated cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1921490">
<a name="1921490"></a>Gustaferro CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. <i>Mayo Clin Proc</i>. 1991;66(10):1064-1073.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/1921490 /pubmed" id="1921490 " target="_blank">1921490 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7159069">
<a name="7159069"></a>Hampel B, Lode H, Wagner J, Koeppe P. Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. <i>Antimicrob Agents Chemother.</i> 1982;22(6):1061-1063. doi:10.1128/AAC.22.6.1061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7159069/pubmed" id="7159069" target="_blank">7159069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7654268">
<a name="7654268"></a>Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. <i>JAMA</i>. 1995;273(1):41-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7654268/pubmed" id="7654268" target="_blank">7654268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-456077">
<a name="456077"></a>Humbert G, Leroy A, Fillastre JP, Godin M. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. <i>Chemotherapy</i>. 1979;25(4):189-195. doi:10.1159/000237839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/456077/pubmed" id="456077" target="_blank">456077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7246123">
<a name="7246123"></a>Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk.<i> Acta Paediatr Scand</i>. 1981;70(3):285-288. doi:10.1111/j.1651-2227.1981.tb16553.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7246123/pubmed" id="7246123" target="_blank">7246123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7073267">
<a name="7073267"></a>La Rosa F, Ripa S, Prenna M, Ghezzi A, Pfeffer M. Pharmacokinetics of cefadroxil after oral administration in humans. <i>Antimicrob Agents Chemother.</i> 1982;21(2):320-322. doi:10.1128/AAC.21.2.320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7073267/pubmed" id="7073267" target="_blank">7073267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34860955">
<a name="34860955"></a>Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. <i>J Pharm Technol</i>. 2018;34(2): 62-81. doi:10.1177/8755122518755402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/34860955/pubmed" id="34860955" target="_blank">34860955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7142092">
<a name="7142092"></a>Leroy A, Humbert G, Godin M, Fillastre JP. Pharmacokinetics of cefadroxil in patients with impaired renal function. <i>J Antimicrob Chemother.</i> 1982;10(suppl B):39-46. doi:10.1093/jac/10.suppl_b.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7142092/pubmed" id="7142092" target="_blank">7142092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290233">
<a name="29290233"></a>Lorrot M, Gillet Y, Gras Le Guen C, Launay E, Cohen R, Grimprel E. Antibiotic therapy of bone and joint infections in children: proposals of the French Pediatric Infectious Disease Group. <i>Arch Pediatr</i>. 2017;24(12S):S36-S41. doi:10.1016/S0929-693X(17)30517-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/29290233/pubmed" id="29290233" target="_blank">29290233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF, Blair JE. The cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195. doi:10.4065/74.2.187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7847529">
<a name="7847529"></a>Nathorst-Böös J, Philipson A, Hedman A, Arvisson A. Renal elimination of ceftazidime during pregnancy. <i>Am J Obstet Gynecol</i>. 1995;172(1 Pt 1):163-166. doi:10.1016/0002-9378(95)90107-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7847529/pubmed" id="7847529" target="_blank">7847529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842069">
<a name="20842069"></a>Peltola H, Pääkkönen M, Kallio P, Kallio MJ; Osteomyelitis-Septic Arthritis Study Group. Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. <i>Pediatr Infect Dis J</i>. 2010;29(12):1123-1128. doi:10.1097/INF.0b013e3181f55a89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/20842069/pubmed" id="20842069" target="_blank">20842069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.2018">
<a name="Pichichero.2018"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2197091">
<a name="2197091"></a>Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. <i>Eur J Clin Microbiol Infect Dis</i>. 1990;9(5):317-323. doi:10.1007/BF01973737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/2197091/pubmed" id="2197091" target="_blank">2197091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32550690">
<a name="32550690"></a>Schachner LA, Torrelo A, Grada A, et al. Treatment of impetigo in the pediatric population: consensus and future directions. <i>J Drugs Dermatol</i>. 2020;19(3):281-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/32550690/pubmed" id="32550690" target="_blank">32550690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2880755">
<a name="2880755"></a>Schedvins K, Moberg PJ. Prevention of postoperative infection in cesarean section after rupture of the membranes. <i>Int J Gynaecol Obstet</i>. 1986;24(3):165-168. doi:10.1016/0020-7292(86)90093-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/2880755/pubmed" id="2880755" target="_blank">2880755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2014;58(10):1496]. <i>Clin Infect Dis</i>. 2012;55(10):e86-e102. doi: 10.1093/cid/cis629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2405586">
<a name="2405586"></a>Smith GH. Oral cephalosporins in perspective. <i>DICP</i>. 1990;24(1):45-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/2405586/pubmed" id="2405586" target="_blank">2405586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Takase.1">
<a name="Takase.1"></a>Takase Z, Shirafuji H, Uchida M. Experimental and clinical studies of cefadroxil in the treatment of infections in the field of obstetrics and gynecology. <i>Chemotherapy (Tokyo).</i> 1980;28(suppl 2):S424-S431.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams.<i> Clin Infect Dis.</i> 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12690270">
<a name="12690270"></a>Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. <i>Pediatr Infect Dis J</i>. 2003;22(4):315-323. doi:10.1097/01.inf.0000059403.21440.2c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/12690270/pubmed" id="12690270" target="_blank">12690270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in: <i>Circulation</i>. 2007;116(15):e376-e377.]. <i>Circulation</i>. 2007;116(15):1736-1754. doi:10.1161/CIRCULATIONAHA.106.183095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7142099">
<a name="7142099"></a>Windorfer A, Bauer P. Pharmacokinetics and clinical studies with cefadroxil in paediatrics. <i>J Antimicrob Chemother</i>. 1982;10(suppl B):S85-S91. doi:10.1093/jac/10.suppl_b.85<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/7142099/pubmed" id="7142099" target="_blank">7142099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350458">
<a name="34350458"></a>Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. <i>J Pediatric Infect Dis Soc</i>. 2021;10(8):801-844. doi:10.1093/jpids/piab027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/34350458/pubmed" id="34350458" target="_blank">34350458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefadroxil-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9212 Version 326.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
